

A study of GCS-100 in combination with chemo-immunotherapy in patients with diffuse large B-cell lymphoma which have relapsed or are refractory to treatment

Submission date 15/10/2008	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/10/2008	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 16/10/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Rebecca Auer

Contact details

St Barts and the London NHS Trust
Dept Medical Oncology
St Barts Hospital
45 Little Britain
West Smithfield
London
United Kingdom
EC1A 7BE

Additional identifiers

Protocol serial number

PR-CS011

Study information

Scientific Title

A phase II study of GCS-100 in combination with chemo-immunotherapy in relapsed or refractory diffuse large B-cell lymphoma

Study objectives

The primary objective of this study is to assess the efficacy of GCS-100 with rituximab, ifosfomide, mesna, carboplatin and etoposide (R-ICE) chemotherapy in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The secondary objective is to determine the safety of GCS-100 in conjunction with cytotoxic chemotherapy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by the London Research Ethics Committee (REC) of Northwick Park Hospital on the 6th October 2008 (ref: 08/H0718/57)

Study design

Interventional, single-arm, single-centre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Interventions

This is a single-arm trial of GCS-100 with R-ICE chemotherapy administered in 21-day cycles (a maximum of four chemotherapy cycles per participant). Each 21-day treatment cycle consists of the following:

Days 1 - 5: GCS-100 160 mg/m²/day intravenously (IV) over 1 hour.

Dosing with GCS-100 will be followed at least 1 hour later by:

Day 1: rituximab 375 mg/m² IV

Days 2: carboplatin dose area under the curve (AUC) = 5 mg/mL x min (maximum 800 mg) IV

Days 2 - 4: ifosfamide 1667 mg/m² IV

Days 2 - 4: mesna 1667 mg/m² IV or oral

Days 2 - 4: etoposide 100 mg/m² IV

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

GCS-100, rituximab, ifosfomide, mesna, carboplatin, etoposide

Primary outcome(s)

1. Response: overall response rate, defined as the sum of the number of CR rate and PR rate. CR and PR will be defined according to the International Harmonisation Project for Lymphoma criteria.
2. Imaging: CT scans will be obtained at baseline and every two cycles to assess for response. They will be evaluated according to the International Harmonisation Project for Lymphoma.

Total duration of follow-up for the primary and secondary outcome measures: 16 weeks.

Key secondary outcome(s)

To determine the safety of GCS-100 in conjunction with cytotoxic chemotherapy by collecting adverse event data and monitoring blood parameters, etc. Total duration of follow-up for the primary and secondary outcome measures: 16 weeks.

Completion date

01/12/2009

Reason abandoned (if study stopped)

Lack of funding/sponsorship

Eligibility

Key inclusion criteria

1. Subject is capable of understanding the purpose and risks of the study and is able to provide written informed consent
2. Subject is male or female, aged at least 18 years
3. Subject has histologically confirmed DLBCL, bidimensionally measurable by computerised tomography (CT) scan, with at least one lesion greater than or equal to 1.5 cm in the greatest diameter. CT scan results must be available prior to dosing to establish eligibility.
4. Subject has relapsed or relapsed/refractory disease following at least two cycles of R-ICE chemotherapy as salvage chemotherapy, without partial response (PR) or complete response (CR)
5. Subject has greater than or equal to 4 weeks elapsed between last chemotherapy or immunotherapy exposure
6. Subject has Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Subject has received high-dose chemotherapy with haematopoietic stem cell support or allogeneic stem cell transplantation (SCT)
3. Subject has rapidly progressive lymphoma or lymphoma threatening organ function
4. Subjects with primary or secondary central nervous system lymphoma
5. Subjects who have had treatment with an experimental (unlicensed) drug within 3 weeks prior to treatment with GCS-100
6. Subject has not recovered from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy
7. Subject has a known history of human immunodeficiency virus-related lymphoma, active hepatitis C, active hepatitis B, or prior history of infection with hepatitis B (HBcAb positive)
8. Subject has a clinically relevant active infection and/or a serious co-morbid medical condition such as recent myocardial infarction (within the last 6 months and no electrocardiographic evidence of acute ischaemia or new conduction system abnormalities), unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, and/or cirrhosis.
9. Subject had major surgery within 4 weeks prior to study day 1

Date of first enrolment

01/12/2008

Date of final enrolment

01/12/2009

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

St Barts and the London NHS Trust

London

United Kingdom

EC1A 7BE

Sponsor information

Organisation

Prospect Therapeutics, Inc. (USA)

Funder(s)

Funder type

Industry

Funder Name

Prospect Therapeutics, Inc. (USA)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes